The Role of Coenzyme Q10 Supplementation in the Treatment of Diabetes, Hyperlipidemia, and Metabolic-Associated Liver Disease: An Updated Overview of Clinical Implications

Currently, the preventive and treatment strategies for metabolic disorders are not fully effective, and many limitations remain with these tools. Coenzyme Q10 (CoQ10) is a new promising antioxidant and anti-inflammatory option that can target the mechanisms involved in the progression of metabolic disorders. The purpose of this study was to assess and summarize the implication of CoQ10 in diabetes, hyperlipidemia, and kidney disease.

Emerging evidence indicated that CoQ10 is effective for familial hypercholesterolemia, familial combined hyperlipidemia, hypercholesterolemia-induced atherosclerosis and cardiac damage, hypercholesterolemia-induced Alzheimer’s-like disease, Type 2 diabetes mellitus, diabetic nephropathy, and metabolic-associated liver disease.

CoQ10 could be a novel agent for the treatment of metabolic disorders including diabetes and its complications, several forms of hyperlipidemia, and metabolic-associated liver disease.